FRANKFURT Mon Mar 31, 2014 5:01am EDT
The logo of Bayer AG is pictured at the Bayer Healthcare subgroup production plant in Wuppertal February 24, 2014.
Credit: Reuters/Ina Fassbender
<span id="articleText"/>FRANKFURT (Reuters) - German drugmaker Bayer said on Monday it won approval in the European Union to widen the use of lung drug Adempas to two life-threatening forms of pulmonary hypertension.
<span id="midArticle_0"/>The EU Commission cleared the use of the drug, also known as riociguat, for the treatment of chronic-thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).
<span id="midArticle_1"/>U.S. authorities approved the drug for the same uses in October.
<span id="midArticle_2"/>Bayer counts Adempas among its most promising new drugs, predicting peak annual sales of more than 500 million euros ($688 million).
<span id="midArticle_3"/>($1 = 0.7271 Euros)
<span id="midArticle_4"/>(Reporting by Ludwig Burger; Editing by Christoph Steitz)
<span id="midArticle_5"/>
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://ift.tt/NWKAHy
<a name="comments"/>Comments (0)
Be the first to comment on reuters.com.
Add yours using the box above.
- Tweet<li class="c4"/><li class="linkedIn" tns="no"/>
- Share this
- <span id="googleTag"/>
Credit: Reuters/Ina Fassbender
<span id="articleText"/>FRANKFURT (Reuters) - German drugmaker Bayer said on Monday it won approval in the European Union to widen the use of lung drug Adempas to two life-threatening forms of pulmonary hypertension.
<span id="midArticle_0"/>The EU Commission cleared the use of the drug, also known as riociguat, for the treatment of chronic-thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).
<span id="midArticle_1"/>U.S. authorities approved the drug for the same uses in October.
<span id="midArticle_2"/>Bayer counts Adempas among its most promising new drugs, predicting peak annual sales of more than 500 million euros ($688 million).
<span id="midArticle_3"/>($1 = 0.7271 Euros)
<span id="midArticle_4"/>(Reporting by Ludwig Burger; Editing by Christoph Steitz)
<span id="midArticle_5"/>
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://ift.tt/NWKAHy
<a name="comments"/>Comments (0)
Be the first to comment on reuters.com.
Add yours using the box above.
via Smart Health Shop Forum http://ift.tt/1hbP8UG
No comments:
Post a Comment